{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:14:42Z","timestamp":1770448482347,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.urology.2017.05.056","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T15:30:39Z","timestamp":1499700639000},"page":"114-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"108","author":[{"given":"Lisly","family":"Ch\u00e9ry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo D.","family":"Borregales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana L.","family":"Urbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H.G.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-9591","authenticated-orcid":false,"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2017.05.056_bib0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0015","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0020","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0025","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","article-title":"Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma","volume":"66","author":"Karam","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.05.056_bib0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2017.05.056_bib0040","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.6004\/jnccn.2014.0106","article-title":"Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines","volume":"12","author":"Tempero","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2017.05.056_bib0045","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1634\/theoncologist.2012-0169","article-title":"The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer","volume":"17","author":"Del Fabbro","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.urology.2017.05.056_bib0050","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejso.2014.11.040","article-title":"Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer","volume":"41","author":"Tan","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0055","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1245\/s10434-014-4285-2","article-title":"Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer","volume":"22","author":"Cooper","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0060","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.juro.2015.08.072","article-title":"Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer","volume":"195","author":"Psutka","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.05.056_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.juro.2015.08.071","article-title":"Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma","volume":"195","author":"Fukushima","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.05.056_bib0070","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","article-title":"Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study","volume":"28","author":"Antoun","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0075","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/oxfordjournals.aje.a009520","article-title":"Epidemiology of sarcopenia among the elderly in New Mexico","volume":"147","author":"Baumgartner","year":"1998","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.urology.2017.05.056_bib0080","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"10.1016\/j.urology.2017.05.056_bib0085","first-page":"i","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","author":"World Health Organization Consultation on Obesity","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.urology.2017.05.056_bib0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urology.2017.05.056_bib0095","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/EJE-12-0405","article-title":"Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial","volume":"167","author":"Schneider","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.urology.2017.05.056_bib0100","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1089\/thy.2015.0334","article-title":"Sorafenib for the treatment of progressive metastatic medullary thyroid cancer: efficacy and safety analysis","volume":"26","author":"Castroneves","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.urology.2017.05.056_bib0105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2017.05.056_bib0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/jcsm.12047","article-title":"Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib","volume":"6","author":"Moryoussef","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.urology.2017.05.056_bib0115","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0120","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0125","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/bjc.2013.58","article-title":"Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients","volume":"108","author":"Huillard","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urology.2017.05.056_bib0130","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000061","article-title":"Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib","author":"Cushen","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0135","doi-asserted-by":"crossref","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","article-title":"Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma","volume":"7","author":"Mir","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.urology.2017.05.056_bib0140","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/j.urolonc.2015.01.011","article-title":"Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma","volume":"33","author":"Sharma","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2017.05.056_bib0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcsm.12033","article-title":"Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients","volume":"6","author":"Lerner","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.urology.2017.05.056_bib0150","first-page":"191","article-title":"Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)","volume":"4","author":"Cella","year":"2006","journal-title":"J Support Oncol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042951730715X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042951730715X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T06:58:23Z","timestamp":1535612303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042951730715X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"alternative-id":["S009042951730715X"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2017.05.056","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2017.05.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}